Core Viewpoint - Heptares Therapeutics-B (02142) has seen a stock price increase of over 5%, currently trading at HKD 13.36, with a transaction volume of HKD 85.495 million [1] Group 1: Fundraising and Share Placement - Heptares Therapeutics-B announced a share placement agreement with a placement agent, agreeing to issue 45.022 million shares at a price of HKD 11.50 per share, which represents a discount of approximately 9.45% compared to the closing price of HKD 12.70 on August 28, 2025 [1] - If all shares are fully subscribed, the net proceeds are expected to be approximately HKD 511.7 million, with about 50% allocated for the development of innovative drug assets, 40% for advancing existing pipeline drug assets in clinical trials, and 10% for working capital and other general corporate purposes [1] Group 2: Financial Performance - Heptares Therapeutics-B reported a mid-term revenue of approximately USD 101 million, representing a year-on-year increase of about 327% [1] - The company achieved a profit of USD 72.999 million during the same period, reflecting a year-on-year growth of 5,125% [1] - Revenue from licensing fees increased from USD 20.8 million to USD 93.7 million, primarily due to strategic collaborations with global pharmaceutical companies and new licensing agreements for innovative products [1] - Revenue from research services and technology licensing fees rose by 164.9%, from USD 2.9 million to USD 7.6 million [1]
港股异动 | 和铂医药-B(02142)再涨超5% 拟折让约9.45%配股 所筹净额用于开拓创新药物资产研发等